

WITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/663,264	09/16/2003	Nicholas W. Warne	22058-544 (AM100664)	1450	
30623 7590 04/06/2007 MINTZ, LEVIN, COHN, FERRIS, GLOVSKY AND POPEO, P.C. ONE FINANCIAL CENTER BOSTON, MA 02111			EXAMINER		
			HISSONG, BRUCE D		
			ART UNIT	PAPER NUMBER	
			1646		
SHORTENED STATUTOR	Y PERIOD OF RESPONSE	MAIL DATE	DELIVER	DELIVERY MODE	
3 MO	NTHS	04/06/2007	PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

		Application No.	Applicant(s)			
		10/663,264	WARNE ET AL.			
	Office Action Summary	Examiner	Art Unit			
		Bruce D. Hissong, Ph.D.	1646			
Period fo	The MAILING DATE of this communication app or Reply	ears on the cover sheet with the c	orrespondence address			
WHIC - Exter after - If NO - Failu Any (ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DANSIONS of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. Depriod for reply is specified above, the maximum statutory period were to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing ed patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tiruly apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).			
Status						
1)	Responsive to communication(s) filed on 11 Ja	nuary 2007.				
2a)⊠	This action is FINAL . 2b) ☐ This action is non-final.					
3) 🗌) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
	closed in accordance with the practice under E	x parte Quayle, 1935 C.D. 11, 4	53 O.G. 213.			
Dispositi	ion of Claims					
5)□ 6)⊠ 7)□	Claim(s) 5-12,17,19-26 and 28-55 is/are pendid 4a) Of the above claim(s) 42-52 is/are withdraw Claim(s) is/are allowed Claim(s) 5-12, 17, 19-26, 28-41, 53-55 is/are re Claim(s) is/are objected to. Claim(s) are subject to restriction and/or	rn from consideration.				
Applicati	ion Papers		·			
10)	The specification is objected to by the Examine The drawing(s) filed on is/are: a) acce Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct The oath or declaration is objected to by the Ex	epted or b) objected to by the drawing(s) be held in abeyance. Se ion is required if the drawing(s) is ob	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).			
Priority (under 35 U.S.C. § 119					
12)[a)	Acknowledgment is made of a claim for foreign All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the priority application from the International Bureau See the attached detailed Office action for a list	s have been received. s have been received in Applicat rity documents have been receiv u (PCT Rule 17.2(a)).	ion No ed in this National Stage			
2) Notice 3) Infor	nt(s) ce of References Cited (PTO-892) ce of Draftsperson's Patent Drawing Review (PTO-948) mation Disclosure Statement(s) (PTO/SB/08) er No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail D 5) Notice of Informal F 6) Other:	ate			

Application/Control Number: 10/663,264 Page 2

Art Unit: 1646

DETAILED ACTION

Continued Examination Under 37 CFR 1.114

1. A request for continued examination under 37 CFR 1.114, including the fee set forth

in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is

eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e)

has been timely paid, the finality of the previous Office action has been withdrawn pursuant to

37 CFR 1.114. Applicant's submission filed on 1/11/2007 has been entered.

2. Claims 5-12, 17, 19-26, and 28-55 are currently pending. Claims 42-52 are

withdrawn as non-elected subject matter. Therefore, claims 5-12, 17, 19-26, 28-41, and 53-55

are the subject of this office action.

Drawings

Objection to the drawing, as set forth on page 3 of the office action mailed on 12/7/2005,

and page 2 of the office action mailed on 6/1/2006, is withdrawn in response to Applicants'

submission of replacement drawings.

Specification

Objection to the specification for improperly identified trademarks, as set froth on page 3

of the office action mailed on 12/7/2005, and page 2 of the office action mailed on 6/1/2006, is

withdrawn in response to Applicants' amendments to the specification to properly identify

trademarks.

Claim Objections

Objections to claims 5 and 9, as set forth on page 3 of the office action mailed on

6/1/2007, are withdrawn in response to Applicants' amendments to the claims.

Art Unit: 1646

Claim Rejections - 35 USC § 112, first paragraph - enablement and written description

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Rejection of claims 5-12, 17, and 19-26 under 35 USC § 112, first paragraph, regarding lack of enablement and written description for a pharmaceutical composition comprising any interleukin (IL)-11, as set forth on pages 4-6 of the prior office action mailed on 6/1/2006, is withdrawn in response to Applicants' amendments to claim 5 to read only on a composition comprising human IL-11.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

- (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made
- 1. Claims 5-12, 17, 19-22, 25, 28-41, and 53-55 <u>remain rejected</u> under 35 USC § 103(a) as being obvious in view of the combination of Savastano *et al* ("Savastano") and Greenwoodvan Meerveld *et al* ("Greenwood"), as set forth on pages 7-10 of the office action mailed on 6/1/2006.

In the response received on 1/11/2007, the Applicants submitted an affidavit under 37 CFR 1.132 to show that the Greenwood document is not proper prior art because authors Greenwood-van Meerveld and Venkova were members of the Greenwood Group doing work under the supervision of Nicholas Warne, who is an Applicant for the instant application, or his colleague James Keith, who is listed as an author of the Greenwood publication. Mr. Warne asserts that although Mr. Keith was involved in coordinating the testing of the IL-11 formulations, he was not involved in developing the presently claimed compositions or methods of using the compositions. For these reasons, the Applicants assert that the Greenwood

Application/Control Number: 10/663,264

Art Unit: 1646

publication is not prior art, and therefore the instant claims cannot properly be obvious in view of any combination using Greenwood.

These arguments have been fully considered and are not persuasive. The affidavit under 37 CFR 1.132 filed 1/11/2007 is insufficient to overcome the rejection of claims 5-12, 17, 19-22, 25, and 28-41 based upon the combination of Savastano and Greenwood as set forth in the last Office action because the submitted 1.132 declaration is not a statement by an author of the relevant art. To sufficiently overcome the rejection, a statement by author James Keith detailing the role of authors Greenwood-van Meerveld and Venkova is required. A statement by a 3rd party, in this case Mr. Warne, as to the roles of authors on a paper in which he was not an author, is insufficient. Applicants are required, under 37 CFR 1.132, to show that the inventorship of the application is correct in that the reference discloses subject matter invented by the Applicant rather than derived from the author or patentee notwithstanding the authorship of the article or the inventorship of the patent. In re Katz, 687 F.2d 450, 455, 215 USPQ 14, 18, (CCPA 1982). Furthermore, where the Applicant is one of the co-authors of a publication cited against his or her application, the publication may be removed as a reference by the filing of affidavits made out by the other authors establishing that the relevant portions of the publication originiated with, or were obtain from, the Applicant. In parte Hirschler, 110 USPQ 384 (Bd. App. 1952).

2. Claims 23, 24, and 26 <u>remain rejected</u> under 35 USC § 103(a) as being obvious in view of the combination of Savastano et al ("Savastano"), Greenwood-van Meerveld et al ("Greenwood"), and Porter, as set forth on page 10 of the office action mailed on 6/1/2006.

The Applicants arguments regarding the proper use of Greenwood, and the response to Applicants arguments, are discussed *supra*. The rejection is maintained for the reasons set forth *supra*, and for the reasons of record on page 10 of the previous office action.

Double Patenting

The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory obviousness-type double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined

Application/Control Number: 10/663,264

Art Unit: 1646

application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., *In re Berg*, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).

A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent either is shown to be commonly owned with this application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement.

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

Claims 5, 17, 19-20, 28-31, and 38-39 <u>remain rejected</u> over claim 13 of application no. 10/360,906, as set forth on page 11 of the office action mailed on 6/1/2006. In the response received on 1/11/2007, the Applicants state that they will address the obviousness-type double-patenting rejection if and when they pay the Issue Fee due for the '906 Application.

Conclusion

No claim is allowable.

This is a Request for Continued Examination (RCE) of Applicants' earlier Application No. 10/663,264. All claims are drawn to the same invention claimed in the earlier application and could have been finally rejected on the grounds and art of record in the next Office action if they had been entered in the earlier application. Accordingly, **THIS ACTION IS MADE FINAL** even though it is a first action in this case. See MPEP § 706.07(b). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no, however, event will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Application/Control Number: 10/663,264 Page 6

Art Unit: 1646

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Bruce D. Hissong, Ph.D., whose telephone number is (571) 272-3324. The examiner can normally be reached M-F from 8:30 am - 5:00 pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Nickol, Ph.D., can be reached at (571) 272-0835. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

BDH Art Unit 1646

> ROBERT S. LANDSMAN, PH.D PRIMARY EXAMINER